Can you take TB-500 and Thymosin Beta-4 Fragment (TB4-Frag 17-23) together?

There is no specific, well-documented interaction rule for combining TB-500 and Thymosin Beta-4 Fragment (TB4-Frag 17-23) in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, TB-500 or Thymosin Beta-4 Fragment (TB4-Frag 17-23)?

TB-500 is currently preclinical only and Thymosin Beta-4 Fragment (TB4-Frag 17-23) is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Healing & Recovery · Comparison

TB-500 vs Thymosin Beta-4 Fragment (TB4-Frag 17-23)

Q: What is the difference between TB-500 and Thymosin Beta-4 Fragment (TB4-Frag 17-23)?

TB-500: TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous protein involved in cell migration, tissue repair, and inflammation regulation. It has shown significant healing properties in preclinical models across muscle, tendon, ligament, and cardiac tissue. Thymosin Beta-4 Fragment (TB4-Frag 17-23): The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling. Both are in the Healing & Recovery category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

TB-500

Preclinical only

TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous protein involved in cell migration, tissue repair, and inflammation regulation. It has shown significant healing properties in preclinical models across muscle, tendon, ligament, and cardiac tissue.

Full profile

Thymosin Beta-4 Fragment (TB4-Frag 17-23)

Research-stage

The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling.

Full profile

	TB-500	Thymosin Beta-4 Fragment (TB4-Frag 17-23)
Category	Healing & Recovery	Healing & Recovery
Also known as	Thymosin Beta-4, Tβ4, TB500	TB4 fragment 17-23, TB-500 active peptide, LKKTETQ, thymosin beta-4 fragment, Ac-LKKTETQ
Evidence	Preclinical only	Research-stage
Dosing range	2mg–10mg mg, twice weekly (loading), weekly (maintenance)	250mcg–1mg mcg–mg, 2–3x weekly
Administration	Subcutaneous injection, Intramuscular injection	Subcutaneous injection, Intramuscular injection
Key side effects	Head rush / lightheadedness (transient), Lethargy at higher doses, Injection site discomfort, Nausea (rare)	Injection site irritation, Mild fatigue (transient), Potential headache, Generally well-tolerated in research applications
Cited sources	2 references	2 references

Key differences

Evidence level differs: TB-500 is preclinical only, while Thymosin Beta-4 Fragment (TB4-Frag 17-23) is research-stage.
Dosing units differ: TB-500 is dosed in mg, Thymosin Beta-4 Fragment (TB4-Frag 17-23) in mcg–mg — they operate at different scales.
Frequency: TB-500 is typically twice weekly (loading), weekly (maintenance); Thymosin Beta-4 Fragment (TB4-Frag 17-23) is 2–3x weekly.

How each works

TB-500

TB-500 promotes healing by upregulating actin, which drives cell migration to injury sites. Animal studies show accelerated repair of muscle tears, tendon injuries, and corneal wounds. It also demonstrates anti-inflammatory properties and has been studied for cardiac tissue repair following ischemic injury.

Thymosin Beta-4 Fragment (TB4-Frag 17-23)

The LKKTETQ sequence was identified in 1994 as the minimum active fragment of thymosin beta-4 responsible for its actin-sequestering and tissue repair activity. This heptapeptide competes with actin monomer binding proteins, promoting cell migration, angiogenesis, and wound healing. Studies confirm it recapitulates the key bioactivity of full TB4 in cell migration and collagen deposition assays.

Read the full TB-500 profile Read the full Thymosin Beta-4 Fragment (TB4-Frag 17-23) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.